KLK4 and hereditary angioedema: A positive phase 3 trial was recently reported for the investigational oral plasma kallikrein inhibitor, sebetralstat, for the on-demand treatment of HAE attacks in patients with HAE-C1INH-Type1/2 (NCT05259917).25